Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:adrenergic agent
go back to main search page
Accession:CHEBI:37962 term browser browse the term
Definition:Any agent that acts on an adrenergic receptor or affects the life cycle of an adrenergic transmitter.
Synonyms:related_synonym: adrenergic agents;   adrenergic drug;   adrenergic drugs;   adrenergic neuron agents;   adrenergics


show annotations for term's descendants           Sort by:
 
aminoglutethimide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G GHRL ghrelin and obestatin prepropeptide multiple interactions EXP Aminoglutethimide promotes the reaction [GHRL protein results in decreased secretion of Progesterone] CTD PMID:22341706 NCBI chr13:66,442,106...66,453,576
Ensembl chr13:66,316,436...66,452,917
JBrowse link
brimonidine tartrate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CREB1 cAMP responsive element binding protein 1 increases phosphorylation
multiple interactions
EXP Brimonidine Tartrate results in increased phosphorylation of CREB1 protein
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Brimonidine Tartrate results in increased phosphorylation of CREB1 protein]
CTD PMID:17680988 NCBI chr15:110,705,548...110,773,037
Ensembl chr15:110,697,408...110,771,755
JBrowse link
carvedilol term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CDH5 cadherin 5 decreases expression
increases expression
EXP Carvedilol results in decreased expression of CDH5 mRNA
Carvedilol results in increased expression of CDH5 protein
CTD PMID:16824628 NCBI chr 6:27,108,560...27,142,145
Ensembl chr 6:27,108,609...27,142,180
JBrowse link
G CTNNB1 catenin beta 1 decreases expression
increases expression
EXP Carvedilol results in decreased expression of CTNNB1 mRNA
Carvedilol results in increased expression of CTNNB1 protein
CTD PMID:16824628 NCBI chr13:25,163,550...25,208,314
Ensembl chr13:25,137,173...25,208,311
JBrowse link
G EDN1 endothelin 1 decreases expression
multiple interactions
EXP Carvedilol results in decreased expression of EDN1 protein
Glyburide inhibits the reaction [Carvedilol results in decreased expression of EDN1 protein]
CTD PMID:18840580 NCBI chr 7:8,752,018...8,758,354
Ensembl chr 7:8,751,695...8,758,348
JBrowse link
G JUP junction plakoglobin increases expression
decreases expression
EXP Carvedilol results in increased expression of JUP protein
Carvedilol results in decreased expression of JUP mRNA
CTD PMID:16824628 NCBI chr12:20,902,395...20,931,208
Ensembl chr12:20,901,396...20,931,211
JBrowse link
cocaine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G EDN1 endothelin 1 increases expression
multiple interactions
EXP Cocaine results in increased expression of EDN1 protein
1,3-ditolylguanidine inhibits the reaction [Cocaine results in increased expression of EDN1 protein]; Haloperidol inhibits the reaction [Cocaine results in increased expression of EDN1 protein]
CTD PMID:9714087 NCBI chr 7:8,752,018...8,758,354
Ensembl chr 7:8,751,695...8,758,348
JBrowse link
dexamethasone term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ALPL alkaline phosphatase, biomineralization associated multiple interactions EXP 2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of ALPL mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of ALPL mRNA CTD PMID:30481989 NCBI chr 6:79,589,695...79,649,646
Ensembl chr 6:79,588,659...79,649,648
JBrowse link
G BCL2L1 BCL2 like 1 multiple interactions EXP [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of BCL2L1 mRNA CTD PMID:30481989 NCBI chr17:35,366,139...35,415,798
Ensembl chr17:35,366,141...35,415,359
JBrowse link
G CASP3 caspase 3 multiple interactions EXP [Troglitazone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CASP3 mRNA CTD PMID:30481989 NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,749...45,763,773
JBrowse link
G CEBPA CCAAT enhancer binding protein alpha increases expression
multiple interactions
EXP Dexamethasone results in increased expression of CEBPA mRNA
[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CEBPA mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CEBPA mRNA]
CTD PMID:11225715 PMID:30481989 NCBI chr 6:43,083,200...43,085,884
Ensembl chr 6:43,083,203...43,085,836
JBrowse link
G COL1A1 collagen type I alpha 1 chain multiple interactions EXP 2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of COL1A1 mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of COL1A1 mRNA CTD PMID:30481989 NCBI chr12:26,379,087...26,397,180
Ensembl chr12:26,379,090...26,397,003
JBrowse link
G CTNNB1 catenin beta 1 multiple interactions EXP 2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CTNNB1 mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CTNNB1 mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CTNNB1 mRNA] CTD PMID:30481989 NCBI chr13:25,163,550...25,208,314
Ensembl chr13:25,137,173...25,208,311
JBrowse link
G CYP17A1 cytochrome P450 17A1 increases expression EXP Dexamethasone results in increased expression of CYP17A1 CTD PMID:19852296 NCBI chr14:113,805,616...113,820,445
Ensembl chr14:113,805,611...113,812,041
JBrowse link
G FABP4 fatty acid binding protein 4, adipocyte multiple interactions EXP 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of FABP4 mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of FABP4 mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of FABP4 mRNA] CTD PMID:30481989 NCBI chr 4:55,096,400...55,101,209
Ensembl chr 4:55,096,404...55,101,897
JBrowse link
G IGF1 insulin like growth factor 1 multiple interactions EXP [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of IGF1 mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of IGF1 mRNA] CTD PMID:30481989 NCBI chr 5:81,762,027...81,909,253
Ensembl chr 5:81,775,970...81,848,037
JBrowse link
G IGF1R insulin like growth factor 1 receptor multiple interactions EXP [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of IGF1R mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of IGF1R mRNA] CTD PMID:30481989 NCBI chr 1:137,383,623...137,691,038
Ensembl chr 1:137,387,925...137,690,666
JBrowse link
G IRS1 insulin receptor substrate 1 decreases expression EXP Dexamethasone results in decreased expression of IRS1 mRNA CTD PMID:19852296 NCBI chr15:128,245,846...128,307,321
Ensembl chr15:128,245,846...128,308,335
JBrowse link
G PPARG peroxisome proliferator activated receptor gamma increases expression
multiple interactions
EXP Dexamethasone results in increased expression of PPARG
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of PPARG mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of PPARG mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of PPARG mRNA]
CTD PMID:19852296 PMID:30481989 NCBI chr13:68,301,566...68,433,951
Ensembl chr13:68,302,655...68,433,947
JBrowse link
G RUNX2 RUNX family transcription factor 2 multiple interactions EXP 2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of RUNX2 mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of RUNX2 mRNA CTD PMID:30481989 NCBI chr 7:40,106,581...40,353,304
Ensembl chr 7:40,106,513...40,459,686
JBrowse link
G SLC2A4 solute carrier family 2 member 4 decreases expression EXP Dexamethasone results in decreased expression of SLC2A4 mRNA; Dexamethasone results in decreased expression of SLC2A4 protein CTD PMID:19852296 NCBI chr12:52,628,746...52,634,965
Ensembl chr12:52,628,450...52,634,967
JBrowse link
G SPP1 secreted phosphoprotein 1 multiple interactions EXP 2,2-bis(4-glycidyloxyphenyl)propane promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of SPP1 mRNA]; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of SPP1 mRNA; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of SPP1 mRNA] CTD PMID:30481989 NCBI chr 8:131,077,786...131,085,334
Ensembl chr 8:131,077,786...131,085,340
JBrowse link
dobutamine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G HK2 hexokinase 2 decreases expression EXP Dobutamine results in decreased expression of HK2 protein CTD PMID:19944370 NCBI chr 3:68,155,656...68,231,187
Ensembl chr 3:68,145,890...68,231,615
JBrowse link
G NOS2 nitric oxide synthase 2 affects response to substance EXP NOS2 protein affects the susceptibility to Dobutamine CTD PMID:20141602 NCBI chr12:44,174,944...44,219,875
Ensembl chr12:44,174,944...44,327,111
JBrowse link
G PYGM glycogen phosphorylase, muscle associated decreases expression EXP Dobutamine results in decreased expression of PYGM protein CTD PMID:19944370 NCBI chr 2:7,409,330...7,421,256
Ensembl chr 2:7,391,064...7,421,261
JBrowse link
icatibant term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G KNG1 kininogen 1 decreases activity EXP icatibant results in decreased activity of KNG1 protein modified form CTD PMID:7890486 NCBI chr13:124,521,276...124,557,384
Ensembl chr13:124,521,277...124,557,376
JBrowse link
imipramine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G FMO1 flavin containing dimethylaniline monoxygenase 1 increases oxidation EXP FMO1 protein results in increased oxidation of Imipramine CTD PMID:6439199 NCBI chr 9:63,860,957...63,895,086
Ensembl chr 9:63,812,103...63,895,077
JBrowse link
phenylephrine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ADRA1B adrenoceptor alpha 1B increases activity EXP Phenylephrine results in increased activity of ADRA1B protein CTD PMID:19376108 NCBI chr16:63,550,123...64,010,838
Ensembl chr16:63,550,128...63,603,034
JBrowse link
G ADRA1D adrenoceptor alpha 1D increases activity EXP Phenylephrine results in increased activity of ADRA1D protein CTD PMID:19376108 NCBI chr17:31,517,021...31,537,361
Ensembl chr17:31,517,021...31,537,361
JBrowse link
G C5 complement C5 affects response to substance EXP C5 protein affects the susceptibility to Phenylephrine CTD PMID:10750764 NCBI chr 1:260,995,662...261,088,868
Ensembl chr 1:260,995,662...261,133,483
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 876
    role 856
      biological role 856
        pharmacological role 383
          neurotransmitter agent 147
            adrenergic agent 28
              (S)-amphetamine + 0
              6alpha-methylprednisolone + 0
              adrenergic agonist + 7
              adrenergic antagonist + 5
              adrenergic uptake inhibitor + 2
              alpha-adrenergic drug + 8
              aminoglutethimide + 1
              amphetamine + 0
              beta-adrenergic drug + 8
              debrisoquin + 0
              dexamethasone + 15
              dexmethylphenidate + 0
              fludrocortisone + 0
              fluticasone propionate 0
              methylphenidate 0
              phentermine + 0
              prednisolone + 0
              prednisone + 0
              sympatholytic agent + 0
              sympathomimetic agent + 7
              tetrahydropalmatine 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 876
    role 856
      application 494
        pharmaceutical 435
          drug 435
            neurotransmitter agent 147
              adrenergic agent 28
                (S)-amphetamine + 0
                6alpha-methylprednisolone + 0
                adrenergic agonist + 7
                adrenergic antagonist + 5
                adrenergic uptake inhibitor + 2
                alpha-adrenergic drug + 8
                aminoglutethimide + 1
                amphetamine + 0
                beta-adrenergic drug + 8
                debrisoquin + 0
                dexamethasone + 15
                dexmethylphenidate + 0
                fludrocortisone + 0
                fluticasone propionate 0
                methylphenidate 0
                phentermine + 0
                prednisolone + 0
                prednisone + 0
                sympatholytic agent + 0
                sympathomimetic agent + 7
                tetrahydropalmatine 0
paths to the root